Loading...
Market
Will Novartis announce another targeted protein degradation partnership by Oct 28, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Novartis official announcements or press releases
Story
Monte Rosa Therapeutics Announces $150M Global License Agreement with Novartis
Oct 28, 2024, 10:30 AM
Monte Rosa Therapeutics ($GLUE) has announced a global license agreement with Novartis ($NVS) to advance T and B Cell-modulating VAV1-directed molecular glue degraders. The deal includes $150 million upfront and potential payments up to $2.1 billion. This agreement aims to enhance Monte Rosa's capabilities in the field of targeted protein degradation, competing with companies like Kymera Therapeutics.
View original story
Similar markets
Yes • 50%
No • 50%
Cancer • 25%
Infectious Diseases • 25%
Autoimmune Diseases • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
